Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 8/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 4/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20409245 | 0.88 | CHEK1 (0.40) | FYNCHEK1FLT3FGFR1FGFR3 | |
| SCHEMBL20409463 | 0.87 | KIT (0.42) | FYNLRRK2CHEK1FLT3RET | |
| SCHEMBL20409423 | 0.85 | CHEK1 (0.47) | FYNLRRK2CHEK1FLT3RET | |
| SCHEMBL20409580 | 0.85 | CHEK1 (0.44) | FYNLRRK2CHEK1FLT3RET | |
| SCHEMBL20409465 | 0.85 | RET (0.49) | FYNCHEK1FLT3FGFR1FGFR3 | |
| SCHEMBL20409246 | 0.84 | IRAK1 (0.48) | FYNLRRK2CHEK1FLT3FGFR1 | |
| SCHEMBL20409426 | 0.84 | IRAK4 (0.46) | FYNCHEK1FLT3RETPIM1 | |
| SCHEMBL20421781 | 0.84 | CCNC (0.44) | FYNLRRK2CHEK1FLT3RET | |
| SCHEMBL20421866 | 0.83 | CDK8 (0.55) | — | |
| SCHEMBL20409455 | 0.82 | CHEK1 (0.42) | FYNLRRK2CHEK1FLT3RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703757-B2 | Compounds and methods for CDK8 modulation and indications therefor | PLEXXIKON INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10703757-B2 | Compounds and methods for CDK8 modulation and indications therefor | PLEXXIKON INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-08-02 | — | — | US | disclosed |
| WO-2018136202-A2 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703757-B2 | Compounds and methods for CDK8 modulation and indications therefor | CDK8, CDK7, CDK18 | FYN 2577/4885LRRK2 1873/4885CHEK1 167/4885 |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | CDK8, CDK7, CDK18 | FYN 2577/4885LRRK2 1873/4885CHEK1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.